1. Home
  2. NAMSW vs GEOS Comparison

NAMSW vs GEOS Comparison

Compare NAMSW & GEOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • GEOS
  • Stock Information
  • Founded
  • NAMSW N/A
  • GEOS 1980
  • Country
  • NAMSW Netherlands
  • GEOS United States
  • Employees
  • NAMSW 29
  • GEOS N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • GEOS Industrial Machinery/Components
  • Sector
  • NAMSW Health Care
  • GEOS Industrials
  • Exchange
  • NAMSW Nasdaq
  • GEOS Nasdaq
  • Market Cap
  • NAMSW N/A
  • GEOS N/A
  • IPO Year
  • NAMSW N/A
  • GEOS 1997
  • Fundamental
  • Price
  • NAMSW $8.90
  • GEOS $9.30
  • Analyst Decision
  • NAMSW
  • GEOS
  • Analyst Count
  • NAMSW 0
  • GEOS 0
  • Target Price
  • NAMSW N/A
  • GEOS N/A
  • AVG Volume (30 Days)
  • NAMSW N/A
  • GEOS 160.2K
  • Earning Date
  • NAMSW N/A
  • GEOS 08-08-2024
  • Dividend Yield
  • NAMSW N/A
  • GEOS N/A
  • EPS Growth
  • NAMSW N/A
  • GEOS N/A
  • EPS
  • NAMSW N/A
  • GEOS 1.19
  • Revenue
  • NAMSW N/A
  • GEOS $136,332,000.00
  • Revenue This Year
  • NAMSW N/A
  • GEOS N/A
  • Revenue Next Year
  • NAMSW N/A
  • GEOS N/A
  • P/E Ratio
  • NAMSW N/A
  • GEOS $7.83
  • Revenue Growth
  • NAMSW N/A
  • GEOS 25.03
  • 52 Week Low
  • NAMSW N/A
  • GEOS $7.27
  • 52 Week High
  • NAMSW N/A
  • GEOS $17.09
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 46.37
  • GEOS 47.60
  • Support Level
  • NAMSW $8.30
  • GEOS $9.00
  • Resistance Level
  • NAMSW $9.77
  • GEOS $10.43
  • Average True Range (ATR)
  • NAMSW 0.27
  • GEOS 0.44
  • MACD
  • NAMSW -0.10
  • GEOS 0.05
  • Stochastic Oscillator
  • NAMSW 28.57
  • GEOS 32.74

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: